

Date of preparation: 2022-04-19

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Conclusion of an annex to the agreement on co-financing of the project entitled “Expansion of the Research and Development Centre of Mabion S.A. – research on the new generation of medicines”

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to the information regarding the co-financing of the project entitled “Expansion of the Research and Development Centre of Mabion S.A. – research on the new generation of medicines” (“Project”), published by Mabion S.A. (“Company”) in current and periodic reports, including most recently in the report for the third quarter of 2021, in which the Company informed about the need to update the schedule of project works and ongoing communication in this regard with the Ministry of Development Funds and Regional Policy (“Ministry”), the Management Board of the Company hereby informs that today, it has concluded, with the Ministry, an annex to the agreement on co-financing of the Project.

Under the annex, the period of eligibility of the expenses for the Project was extended to 31 December 2023 (previously 31 December 2021). Furthermore, due to the inclusion of an additional research area in the Company’s activity, i.e. vaccine therapies, the objective and material and financial scope of the Project were changed to the extent enabling inclusion of the above-mentioned research area into the Project.

The annex was concluded at the request of the Company due to the circumstances affecting the implementation of the Project in previous years, i.e. at first the issues related to the financing of own contribution, and then the COVID-19 pandemic and the need to incorporate the area of vaccine therapies.

The Company informed about the conclusion of the agreement on the Project co-financing in Current Report no. 42/2018 of 11 June 2018.